Evaluating the role of FAMIly history of cancer and diagnosis of multiple neoplasms in cancer patients receiving PD-1/PD-L1 checkpoint inhibitors: the multicenter FAMI-L1 study

被引：10

作者：

Cortellini, Alessio ^{[1
,2
]}

Buti, Sebastiano ^{[3
]}

Bersanelli, Melissa ^{[3
,4
]}

Giusti, Raffaele ^{[5
]}

Perrone, Fabiana ^{[3
]}

Di Marino, Pietro ^{[6
]}

Tinari, Nicola ^{[7
]}

De Tursi, Michele ^{[7
]}

Grassadonia, Antonino ^{[7
]}

Cannita, Katia ^{[1
]}

Tessitore, Alessandra ^{[2
]}

Zoratto, Federica ^{[8
]}

Veltri, Enzo ^{[8
]}

Malorgio, Francesco ^{[9
]}

Russano, Marco ^{[10
]}

Anesi, Cecilia ^{[10
]}

Zeppola, Tea ^{[10
]}

Filetti, Marco ^{[5
]}

Marchetti, Paolo ^{[5
,11
,12
,13
]}

Botticelli, Andrea ^{[11
]}

Cappellini, Gian Carlo Antonini ^{[13
]}

De Galitiis, Federica ^{[13
]}

Vitale, Maria Giuseppa ^{[14
]}

Rastelli, Francesca ^{[15
]}

Pergolesi, Federica ^{[15
]}

Berardi, Rossana ^{[16
]}

Rinaldi, Silvia ^{[16
]}

Tudini, Marianna ^{[17
]}

Silva, Rosa Rita ^{[17
]}

Pireddu, Annagrazia ^{[18
]}

Atzori, Francesco ^{[18
]}

Iacono, Daniela ^{[19
]}

Migliorino, Maria Rita ^{[19
]}

Gelibter, Alain ^{[12
]}

Occhipinti, Mario Alberto ^{[12
]}

Martella, Francesco ^{[12
]}

Inno, Alessandro ^{[20
]}

Gori, Stefania ^{[21
]}

Bracarda, Sergio ^{[21
]}

Zannori, Cristina ^{[22
]}

Mosillo, Claudia ^{[22
]}

Parisi, Alessandro ^{[1
,2
]}

Porzio, Giampiero ^{[1
,2
]}

Mallardo, Domenico ^{[23
]}

Fargnoli, Maria Concetta ^{[2
,24
]}

Tiseo, Marcello ^{[3
,4
]}

Santini, Daniele ^{[10
]}

Ascierto, Paolo A. ^{[23
]}

Ficorella, Corrado ^{[1
,2
]}

机构：

[1] St Salvatore Hosp, Med Oncol, Laquila, Italy

[2] Univ Aquila, Dept Biotechnol & Appl Clin Sci, Laquila, Italy

[3] Univ Hosp Parma, Med Oncol, Parma, Italy

[4] Univ Parma, Dept Med & Surg, Parma, Italy

[5] Azienda Osped Univ St Andrea, UOC Oncol Med, Rome, Italy

[6] SS Annunziata Hosp, Clin Oncol Unit, Chieti, Italy

[7] Univ G DAnnunzio, Dept Med Oral & Biotechnol Sci, Chieti, Italy

[8] Santa Maria Goretti Hosp, Med Oncol, Latina, Italy

[9] Santo Spirito Hosp, Med Oncol, Pescara, Italy

[10] Campus Biomed Univ, Med Oncol, Rome, Italy

[11] Sapienza Univ Rome, Med Oncol, Rome, Italy

[12] Policlin Umberto 1, Med Oncol B, Rome, Italy

[13] IDI IRCCS, Med Oncol, Rome, Italy

[14] Univ Hosp Modena, Med Oncol, Modena, Italy

[15] Fermo Area Vasta 4, Med Oncol, Fermo, Italy

[16] Univ Politecn Marche, Oncol Clin, Ancona, Italy

[17] AV2 Fabriano ASUR Marche, Med Oncol, Fabriano, Italy

[18] Univ Hosp Cagliari, Med Oncol Unit, Cagliari, Italy

[19] St Camillo Forlanini Hosp, Pulm Oncol Unit, Rome, Italy

[20] G Mazzini Hosp, Med Oncol, Teramo, Italy

[21] Sacro Cuore Don Calabria Hosp, Med Oncol Unit, IRCCS, Verona, Italy

[22] Azienda Osped S Maria, Med Oncol, Terni, Italy

[23] IRCCS Fdn G Pascale, Melanoma Canc Immunotherapy & Dev Therapeut Unit, Ist Nazl Tumori, Naples, Italy

[24] San Salvatore Hosp, Dermatol, Laquila, Italy

来源：

ONCOIMMUNOLOGY | 2020年 / 9卷 / 01期

关键词：

Family history of cancer; multiple neoplasms; DDR genes; immune checkpoint inhibitors; immunotherapy; PD-1; CELL LUNG-CANCER; DNA-DAMAGE RESPONSE; ADVERSE EVENTS; ELDERLY-PATIENTS; PD-1; BLOCKADE; ASSOCIATION; NIVOLUMAB; TUMORS; MELANOMA; GENES;

D O I：

10.1080/2162402X.2019.1710389

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Background: We investigate the role of family history of cancer (FHC) and diagnosis of metachronous and/or synchronous multiple neoplasms (MN), during anti-PD-1/PD-L1 immunotherapy. Design: This was a multicenter retrospective study of advanced cancer patients treated with anti-PD-1/PD-L1 immunotherapy. FHC was collected in lineal and collateral lines, and patients were categorized as follows: FHC-high (in case of cancer diagnoses in both the lineal and collateral family lines), FHC-low (in case of cancer diagnoses in only one family line), and FHC-negative. Patients were also categorized according to the diagnosis of MN as follows: MN-high (>2 malignancies), MN-low (two malignancies), and MN-negative. Objective response rate (ORR), progression-free survival (PFS), overall survival (OS), and incidence of immune-related adverse events (irAEs) of any grade were evaluated. Results: 822 consecutive patients were evaluated. 458 patients (55.7%) were FHC-negative, 289 (35.2%) were FHC-low, and 75 (9.1%) FHC-high, respectively. 29 (3.5%) had a diagnosis of synchronous MN and 94 (11.4%) of metachronous MN. 108 (13.2%) and 15 (1.8%) patients were MN-low and MN-high, respectively. The median follow-up was 15.6 months. No significant differences were found regarding ORR among subgroups. FHC-high patients had a significantly longer PFS (hazard ratio [HR] = 0.69 [95% CI: 0.48-0.97], p = .0379) and OS (HR = 0.61 [95% CI: 0.39-0.93], p = .0210), when compared to FHC-negative patients. FHC-high was confirmed as an independent predictor for PFS and OS at multivariate analysis. No significant differences were found according to MN categories. FHC-high patients had a significantly higher incidence of irAEs of any grade, compared to FHC-negative patients (p = .0012). Conclusions: FHC-high patients seem to benefit more than FHC-negative patients from anti-PD-1/PD-L1 checkpoint inhibitors.

引用

页数：10

共 38 条

[31] Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response to Anti-PD-1 Therapy [J].

Taube, Janis M. ;

Klein, Alison ;

Brahmer, Julie R. ;

Xu, Haiying ;

Pan, Xiaoyu ;

Kim, Jung H. ;

Chen, Lieping ;

Pardoll, Drew M. ;

Topalian, Suzanne L. ;

Anders, Robert A. .

CLINICAL CANCER RESEARCH, 2014, 20 (19) :5064-5074

[32] Alterations in DNA Damage Response and Repair Genes as Potential Marker of Clinical Benefit From PD-1/PD-L1 Blockade in Advanced Urothelial Cancers [J].

Teo, Min Yuen ;

Seier, Kenneth ;

Ostrovnaya, Irina ;

Regazzi, Ashley M. ;

Kania, Brooke E. ;

Moran, Meredith M. ;

Cipolla, Catharine K. ;

Bluth, Mark J. ;

Chaim, Joshua ;

Al-Ahmadie, Hikmat ;

Snyder, Alexandra ;

Carlo, Maria I. ;

Solit, David B. ;

Berger, Michael F. ;

Funt, Samuel ;

Wolchok, Jedd D. ;

Iyer, Gopa ;

Bajorin, Dean F. ;

Callahan, Margaret K. ;

Rosenberg, Jonathan E. .

JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (17) :1685-+

[33] Early Immune-Related Adverse Events and Association with Outcome in Advanced Non-Small Cell Lung Cancer Patients Treated with Nivolumab: A Prospective Cohort Study [J].

Teraoka, Shunsuke ;

Fujimoto, Daichi ;

Morimoto, Takeshi ;

Kawachi, Hayato ;

Ito, Munehiro ;

Sato, Yuki ;

Nagata, Kazuma ;

Nakagawa, Atsushi ;

Otsuka, Kojiro ;

Uehara, Keiichiro ;

Imai, Yukihiro ;

Ishida, Kaori ;

Fukuoka, Junya ;

Tomii, Keisuke .

JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (12) :1798-1805

[34] Mismatch Repair Deficiency as a Predictive Biomarker for Immunotherapy Efficacy [J].

Viale, Giulia ;

Trapani, Dario ;

Curigliano, Giuseppe .

BIOMED RESEARCH INTERNATIONAL, 2017, 2017

[35] Multiple primary tumours: challenges and approaches, a review [J].

Vogt, Alexia ;

Schmid, Sabine ;

Heinimann, Karl ;

Frick, Harald ;

Herrmann, Christian ;

Cerny, Thomas ;

Omlin, Aurelius .

ESMO OPEN, 2017, 2 (02)

[36] 'Coming down the line' - Patients' understanding of their family history of common chronic disease [J].

Walter, FM ;

Emery, J .

ANNALS OF FAMILY MEDICINE, 2005, 3 (05) :405-414

[37] Genetics and biology of prostate cancer [J].

Wang, Guocan ;

Zhao, Di ;

Spring, Denise J. ;

DePinho, Ronald A. .

GENES & DEVELOPMENT, 2018, 32 (17-18) :1105-1140

[38] Comutations in DNA Damage Response Pathways Serve as Potential Biomarkers for Immune Checkpoint Blockade [J].

Wang, Zhijie ;

Zhao, Jing ;

Wang, Guoqiang ;

Zhang, Fan ;

Zhang, Zemin ;

Zhang, Fan ;

Zhang, Yuzi ;

Dong, Hua ;

Zhao, Xiaochen ;

Duan, Jianchun ;

Bai, Hua ;

Tian, Yanhua ;

Wan, Rui ;

Han, Miao ;

Cao, Yan ;

Xiong, Lei ;

Liu, Li ;

Wang, Shuhang ;

Cai, Shangli ;

Mok, Tony S. K. ;

Wang, Jie .

CANCER RESEARCH, 2018, 78 (22) :6486-6496

← 1 2 3 4 →